Brain co‐delivery of first‐line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy

Glioblastoma (GBM) is a central nervous system tumor with poor prognosis due to the rapid development of resistance to mono chemotherapy and poor brain targeted delivery. Chemoimmunotherapy (CIT) combines chemotherapy drugs with activators of innate immunity that hold great promise for GBM synergist...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanjie, Wang, Wendie, Zhang, Dongya, Sun, Yajing, Li, Fangzhou, Zheng, Meng, Lovejoy, David B., Zou, Yan, Shi, Bingyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190947/
https://www.ncbi.nlm.nih.gov/pubmed/37325609
http://dx.doi.org/10.1002/EXP.20210274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190947/
https://www.ncbi.nlm.nih.gov/pubmed/37325609
http://dx.doi.org/10.1002/EXP.20210274

Ejemplares similares